Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.

Krakower D, Mayer KH.

Curr HIV/AIDS Rep. 2011 Dec;8(4):241-8. doi: 10.1007/s11904-011-0094-4. Review.

2.

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Celum C, Baeten JM.

Curr Opin Infect Dis. 2012 Feb;25(1):51-7. doi: 10.1097/QCO.0b013e32834ef5ef. Review.

3.

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.

PMID:
21284497
4.
5.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Uthman OA, Okoromah CA.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007189. doi: 10.1002/14651858.CD007189.pub3. Review.

PMID:
22786505
6.

Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Baeten JM, Grant R.

Curr HIV/AIDS Rep. 2013 Jun;10(2):142-51. doi: 10.1007/s11904-013-0157-9. Review.

7.

[HIV preexposure prophylaxis].

Olczak A, Grabczewska E.

Przegl Epidemiol. 2012;66(1):79-82. Review. Polish.

8.

Oral antiretroviral chemoprophylaxis: current status.

Baeten J, Celum C.

Curr Opin HIV AIDS. 2012 Nov;7(6):514-9. doi: 10.1097/COH.0b013e3283582d30. Review.

9.

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.

Duwal S, Schütte C, von Kleist M.

PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/fb73d0f4-1cd8-481d-bddd-20439896102a.

10.

Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.

Rahman SM, Vaidya NK, Zou X.

J Theor Biol. 2014 Apr 21;347:151-9. doi: 10.1016/j.jtbi.2013.12.021. Epub 2013 Dec 28.

PMID:
24380779
11.

Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.

Li J, Dufrene SL, Okulicz JF.

Ann Pharmacother. 2014 Apr;48(4):507-18. doi: 10.1177/1060028014520880. Epub 2014 Jan 28. Review.

PMID:
24473492
12.

Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Baeten JM, Haberer JE, Liu AY, Sista N.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9. doi: 10.1097/QAI.0b013e3182986f69. Review.

13.

HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.

Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367.

14.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Okoromah CA.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007189. doi: 10.1002/14651858.CD007189.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;7:CD007189.

PMID:
19160329
15.

Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.

Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA.

J Infect Dis. 2014 Jun 15;209(12):1916-20. doi: 10.1093/infdis/jiu026. Epub 2014 Jan 16.

16.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

17.

HIV preexposure prophylaxis: new data and potential use.

Celum CL.

Top Antivir Med. 2011 Dec;19(5):181-5.

19.

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.

Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Priddy FH.

PLoS One. 2012;7(4):e33103. doi: 10.1371/journal.pone.0033103. Epub 2012 Apr 12.

20.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

Supplemental Content

Support Center